Press Releases – NASDAQ (US) Website

Press Releases

Jun 16, 2017
BeiGene Presents Initial Phase 1 Data on BTK Inhibitor BGB-3111 Combined with Obinutuzumab at the 14th International Conference on Malignant Lymphoma and Announces Additional Planned Global Registrational Trials for BGB-3111    read more...
Jun 15, 2017
BeiGene Presents Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Waldenström’s Macroglobulinemia at the 14th International Conference on Malignant Lymphoma    read more...
Jun 14, 2017
BeiGene Presents Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the 14th International Conference on Malignant Lymphoma    read more...
Jun 07, 2017
BeiGene to Present at Upcoming Investor Conferences    read more...
Jun 07, 2017
BeiGene to Present Data on BGB-3111 at the 14th International Conference on Malignant Lymphoma and to Host Conference Call    read more...
Jun 05, 2017
BeiGene Presents Initial Phase 1 Data on Anti-PD-1 Antibody BGB-A317 Combined with PARP Inhibitor BGB-290 at the 2017 American Society for Clinical Oncology Annual Meeting    read more...
May 17, 2017
BeiGene to Present at the 2017 UBS Global Healthcare Conference    read more...
May 10, 2017
BeiGene Reports First Quarter 2017 Financial Results    read more...
Apr 21, 2017
BeiGene Announces Initiation of First Pivotal Study in China of PD-1 Antibody BGB-A317    read more...
Apr 21, 2017
BeiGene Announces Presentation on a Phase I Study of PD-1 Antibody BGB-A317 in Combination with PARP Inhibitor BGB-290 at the 2017 American Society of Clinical Oncology Annual Meeting    read more...
Apr 02, 2017
BeiGene Presents Phase IB Data on RAF Dimer Inhibitor BGB-283 at the 2017 American Association for Cancer Research Annual Meeting    read more...
Mar 22, 2017
BeiGene Reports Fourth Quarter and Full Year 2016 Financial Results    read more...
Mar 09, 2017
BeiGene Announces Initiation of Pivotal Study in China with BTK Inhibitor BGB-3111 in Patients with Relapsed or Refractory CLL/SLL    read more...
Mar 07, 2017
BeiGene and Guangzhou Development District Establish Joint Venture to Build Biologics Manufacturing Facility    read more...
Mar 02, 2017
BeiGene Announces Initiation of First Pivotal Study in China with BTK Inhibitor BGB-3111    read more...
Mar 02, 2017
BeiGene Announces Presentation of Phase IB Data on BGB-283 at the 2017 American Association for Cancer Research Annual Meeting    read more...
Feb 27, 2017
BeiGene to Present at the Cowen and Company 37th Annual Health Care Conference    read more...
Feb 08, 2017
BeiGene to Participate in the LEERINK Partners 6th Annual Global Healthcare Conference    read more...
Jan 25, 2017
BeiGene Initiates Global Phase III Trial of the BTK Inhibitor BGB-3111 in Waldenström’s Macroglobulinemia    read more...
Dec 30, 2016
BeiGene Announces First Patient Dosing in China Phase I Trial with Investigational Anti-PD-1 Monoclonal Antibody BGB-A317    read more...